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In the course of our work four (4) patent applications were 
filed. 1) Electromedical device for intra operative radiation 
therapy by the means of ionizing radiation with energy higher 
than 9 MeV. 2) Electron irradiation head position regulation 
system of electromedical device for intra operative radiation 
therapy. 3) Electron beam forming system in treatment head 
of the mobile intra operative accelerator. 4) Electromedical 
device for intra operative radiation therapy with electronic 
control of ionization irradiation beam placement. 
Applications 1-3 have been granted a patent, application 4 is 
still pending. 
Conclusions: The IntraLine accelerator meets all of the 
objectives set for the demonstrator. However, future clinical 
application of this device may possibly require new 
mechanical and electrical schemes aiming at minimizing the 
device’s size and weight. Current work also focuses on the 
device’s motion support control system, as well as its 
treatment planning system. 
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Purpose/Objective: A 4D detector array (ArcCHECK, Sun 
Nuclear) has been developed specifically for rotational 
delivery QA and dosimetry. The purpose of this study was to 
evaluate the feasibility of the ArcCHECK as a patient specific 
QA device for different rotational treatment techniques. We 
report the preliminary results of the evaluation and discuss 
the determination of clinically relevant acceptance criteria. 
Materials and Methods: The ArcCHECK device is a cylindrical 
water-equivalent phantom (PMMA) with a three-dimensional 
array (21 cm diameter and length) of 1386 diode detectors 
arranged in a spiral pattern at depth 2.9 cm with 10 mm 
sensor spacing.. The proprietary SNC Patient software is used 
to compare the device measured planar dose distribution to 
that calculated by the TPS.  
We analyzed 40 treatment plans: 19 Dynamic Conformal Arc 
Therapy (DCAT) treatment plans for stereotactic 
radiotherapy of brain tumors, 11 Static Conformal Arc 
Therapy (SCAT) treatment plans for stereotactic radiotherapy 
of lung tumors and 10 Volumetric Modulated Arc Therapy 
(VMAT) treatment plans for different treatment sites (5 lung, 
3 head & neck, 1 liver and 1 head). The DCAT plans were 
constructed and calculated using the iPlan 3.0 TPS while the 
Oncentra Masterplan 4.3 TPS was used for the other plans. All 
the patient plans were recalculated for the ArcCHECK 
phantom geometry. For the DCAT plans a Monte Carlo 
algorithm was used, while a Collapsed Cone algorithm was 
used for the SCAT and VMAT plans. 
All measurements were carried out with 6 MV photon beams 
on a Varian TrueBeam STx linear accelerator using the 
ArcCHECK phantom with a solid homogenous PMMA insert. 
The pass rate of the g index was used to compare the 
measured and the calculated dose distribution. We used 
absolute dose mode and local dose difference normalization 
for the comparison as well as the minimum dose threshold 
equal to 10%. Two levels of acceptance criteria were tested 
for the comparison: 3%/3mm and 2%/2mm. 
Results: The measurements performed in the course of 
approximately 7 weeks showed a stable performance of the 
ArcCHECK device. Average g-passing rates for all treatment 
plans, including the passing rate intervals, are shown in Table 
1. Differences in passing rates between the DCAT, SCAT and 
VMAT plans are all statistically significant (p < 0.05) except 
between DCAT and SCAT plans using the 3%/3mm criteria. 
 
 
 
Conclusions: In general the ArcCHECK device showed to be a 
convenient and robust tool for pre-treatment QA which is 
easy to use and handle. However we found that in order to 
sharpen the QA acceptance criteria and become more 
sensitive to the clinically relevant dose differences, it 
requires tailoring which takes into account beam delivery 
technique as well as 3D dose distribution.  
Further work is ongoing to include in the QA routines 3DVH 
comparison and the possibility to estimate the dose 
distribution in the patient. 
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Purpose/Objective: To compare three 2D-arrays of 
detectors, which have different distances between detectors 
and chamber sizes, used to verify SBRT treatments with 
Octavius 4D. 
Materials and Methods: Ten SBRT treatments of different 
locations were selected (including lung, liver, vertebra and 
nose) for the study. In one of them, four additional plans 
were made, in three of which the same leaf was shifted a 
distance of 2, 3 and 4 mm (one distance for each plan) in all 
beams; in the fourth plan, the leaves positions were 
randomly changed for overdosing the spinal cord. The 
intention of the four modified plans was to study the 2D-
array sensitivity to detect errors or changes. All treatments 
were computed by the treatment planning system (TPS) 
RayStation 4.0.3.4 (RaySearch Laboratories, Stockholm, 
Sweden) that uses the collapsed cone convolution algorithm. 
A linear accelerator (Elekta Synergy) was used to verify the 
SBRT treatments with 6 MV photons. 
The three 2D-arrays (PTW-Freiburg, Germany) that were used 
are: Octavius 729 with 729 ionization chambers with 
dimensions of 5x5x5 mm3 and a distance of 10 mm between 
chamber centers, Octavius 1000 SRS with smaller 977 liquid 
ionization chambers (2.3x2.3x0.5 mm3) and higher resolution 
(distance of 2.5mm between chamber centers in the central 
area and 5 mm in the outer area) and Octavius 1500 with 
1405 chambers with a size of 4.4x4.4x3 mm3 and a chamber 
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spacing of 7.1 mm center to center. During measurements, 
the 2D-arrays are embedded in the Octavius 4D phantom. 
The software used with Octavius 4D to compare the TPS 
calculated treatments and the measured treatments in the 
accelerator, was the Verisoft 6.0. Octavius 4D measures 
planar dose distributions depending on the gantry angle and 
after that, the software reconstructs a 3D dose distribution. 
To obtain the differences between dose distributions, 
calculated with the TPS vs measured on the accelerator, the 
local 3D gamma-index (3%, 3 mm criterion) with a threshold 
of 10% for the maximum absorbed dose was used. 
Results: The global results were: 99.97±0.10% of evaluated 
voxels passed the gamma-index criterion for Octavius 1000 
SRS; 99.44 ±0.39 % for Octavius 1500; and 95.37±1.33 % for 
Octavius 729. There is a clear relationship between the 
resolution of the 2D-array and the number of points passing 
the 3D gamma-index criterion. 
Table I shows the results obtained by comparing the 
measured modified plans and the original plan given by the 
TPS. Here we could see that as the chamber sizes is less, the 
detector is more sensitive to detect the forced variation in 
the leaves position due to the signal averaging is lower. 
 
Conclusions: Octavius 1000 SRS is the most suitable to verify 
SBRT. It gives the best results for the 3D gamma-index 
criterion due to it has the smallest distance between 
chambers and it’s the most sensitive detecting the errors or 
position variations in the leaves due to the smallest size of its 
chambers. Octavius 1500 is also useful to verify SBRT and 
allows to measure IMRT treatments due to its size.  
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Purpose/Objective: To examine the UK’s current practices in 
CSRS. 
Materials and Methods: A questionnaire, designed to include 
Gamma Knife (GK), Cyberknife (CK), Linac-Based (LB) and 
TomoTherapy (TT), was sent to 70 radiotherapy and 
radiosurgery centres in the UK between June and November 
2014.  
Results: 85.7% (60/70) of centres responded. Of these, 33.3% 
(20/60) were performing CSRS, 8.3% (5/60) are in the process 
of implementing CSRS and are planning to be clinical by 
August 2015 and 8.3% (5/60) are planning to implement CSRS 
by October 2016. The remaining 50% (30/60) are not 
performing CSRS and do not plan to implement it before 
October 2016. 
25% (5/20) treat up to 4 patients per month, 45% (9/20) treat 
5-15 patients per month and 30% (6/20) treat more than 16 
patients per month. There are 29 machines used for CSRS in 
the country (14 LB, 6 CK, 7 GK and 1 TT) but they are not all 
dedicated to CSRS. The most commonly used techniques are 
non-coplanar static fields (used by 85% of centres), non-
coplanar dynamic conformal arcs (20%) and circular 
collimator arcs (20%). 70% are using 6MV photons and 30% 
using Cobalt-60 (~1.25MV). A range of imaging modalities is 
used for outlining: Fused CT&MR (70%), MR (60%), CT (50%), 
Angiogram (45%), PET (20%) and Fused CT&PET (10%).  
A large range of answers were given for the most common 
prescription isodose. Two peaks were seen: 20% (4/20) 
usually prescribe to the 45-50% isodose, 20% (4/20) to the 80-
85% isodose, with the remaining centres prescribing between 
these 2 groups and up to the 95-100% isodose.  
Patient specific QA measurements are performed on every 
plan by 35% (7/20) and 65% (13/20) decreased the 
measurements taken after 10-25 plans. The results show a 
wide range of detectors and phantoms being used for QA 
measurements.  
The most common treatment sites are solitary and multiple 
brain metastases, followed by acoustic neuromas, 
meningiomas and AVMs. The majority of centres (70%) stated 
that treatment delivery usually takes less than 1 hour. 
The results show that pre-treatment and during-treatment 
imaging is used in the majority of CK and LB treatments but 
not used at all in GK. When asked for a figure of acceptable 
setup accuracy, 50% stated sub-millimetre accuracies with 
the remaining ranging from 1-2mm. 
Conclusions: The number of centres delivering CSRS is 
increasing and will continue to increase in the next 2-3 years. 
This is particularly the case with LB radiosurgery. Most 
centres are aiming to expand their service to treat more 
indications and more patients. There is a wide variety of 
planning procedures, QA methods, prescription protocols and 
delivery practices despite the fact that the indications 
treated by all centres are comparable.  
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Purpose/Objective: To compare the daily dose measurement 
of Flattening Filter (FF) beams with Flattening Filter Free 
(FFF) beams of 6MV and 10MV in Elekta Versa HD, and to 
evaluate the performance of using daily constancy check 
device with lowered dose rate in FFF beams. 
Materials and Methods: The daily assurance measurement, 
including Central Axis Dose (CAX), beam flatness, beam 
symmetry (GT and LR direction), and beam quality factor 
